

CTX-2026

Cat. No.:	HY-P99179
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer ^[1] .	
In Vitro	<p>CTX-2026 (1 µg/mL; 12 h) redirects the cytotoxic activity of Vγ9Vδ2 T cells from multiple donors against BTN3A1⁺OVCAR3 cells or primary HGSOc cells^[1].</p> <p>CTX-2026 (1 µg/mL; 6 d) shows a rescuing effect on nonablated CD45⁺ T cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
In Vivo	<p>CTX-2026 (5 mg/kg; i.p. for 15 days every 3 days once) effects the tumor growth of NY-OVCAR3 tumor mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
	Animal Model:	NSG mice with NY-OVCAR3 tumors ^[1]
	Dosage:	5 mg/kg
	Administration:	Intraperitoneal injection; 5 mg/kg 3 days for once; for 15 days
	Result:	Effectively delayed malignant progression from nine different donors.

REFERENCES

[1]. Payne KK, et al. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. Science. 2020 Aug 21;369(6506):942-949.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA